These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 8739811

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM, Sedek G, Fotteler B, Zürcher G, Nielsen T, Aitken JW.
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
    Jorga KM.
    Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
    Gasser UE, Jorga K, Crevoisier C, Hovens SE, van Giersbergen PL.
    Eur Neurol; 1999 May; 41(4):206-11. PubMed ID: 10343151
    [Abstract] [Full Text] [Related]

  • 12. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G.
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T, Machado R, Rocha JF, Fernandes-Lopes C, Costa R, Torrão L, Loureiro AI, Falcão A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P.
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM, Nicholl DJ.
    Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160
    [Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
    Jorga K, Banken L, Fotteler B, Snell P, Steimer JL.
    Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
    [Abstract] [Full Text] [Related]

  • 17. Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism.
    Jorga KM, Davis TL, Kurth MC, Saint-Hilaire MH, LeWitt PA, Fotteler B, Zürcher G, Rabbia M.
    Clin Neuropharmacol; 2000 Jun; 23(2):98-105. PubMed ID: 10803800
    [Abstract] [Full Text] [Related]

  • 18. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M, Yokochi M, Kuno S, Hattori Y, Tsukamoto Y, Narabayashi H, Tohgi H, Mizuno Y, Kowa H, Yanagisawa N, Kanazawa I.
    J Neural Transm (Vienna); 1997 Jun; 104(2-3):229-36. PubMed ID: 9203084
    [Abstract] [Full Text] [Related]

  • 19. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.
    Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S.
    Neurology; 1998 May; 50(5 Suppl 5):S54-9. PubMed ID: 9591523
    [Abstract] [Full Text] [Related]

  • 20. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
    Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R, Perret JE.
    Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.